Phillip Md Et Al Frost Buys 47,537 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock in a transaction dated Tuesday, January 28th. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $69,879.39. Following the completion of the transaction, the chief executive officer now owns 213,234,014 shares of the company's stock, valued at approximately $313,454,000.58. This represents a 0.02 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were bought at an average price of $1.48 per share, for a total transaction of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock. The stock was bought at an average price of $1.59 per share, with a total value of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were bought at an average price of $1.56 per share, for a total transaction of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The shares were bought at an average price of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock. The stock was purchased at an average cost of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

OPKO Health stock traded up $0.01 during midday trading on Friday, hitting $1.52. 3,805,176 shares of the company were exchanged, compared to its average volume of 2,246,060. The business has a fifty day simple moving average of $1.52 and a two-hundred day simple moving average of $1.52. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The firm has a market capitalization of $1.04 billion, a PE ratio of -8.00 and a beta of 1.63. OPKO Health, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $1.76.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.13. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $173.60 million for the quarter, compared to analysts' expectations of $181.32 million. During the same quarter last year, the company earned ($0.11) EPS. On average, sell-side analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Barrington Research reiterated an "outperform" rating and issued a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th. HC Wainwright restated a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, January 8th. Finally, StockNews.com lowered shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Wednesday, January 15th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC boosted its stake in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 11,089 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new position in OPKO Health during the third quarter worth approximately $45,000. Algert Global LLC purchased a new position in OPKO Health during the second quarter worth approximately $44,000. Private Advisor Group LLC grew its holdings in OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 25,000 shares during the period. Finally, World Investment Advisors LLC purchased a new stake in shares of OPKO Health in the third quarter valued at approximately $61,000. Hedge funds and other institutional investors own 64.63% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.